RxDoctor Payments Data

Cathy Hennies, MD

Family Medicine · Rapid City, SDNPI 1396749768

Payments from drug & device makers

$228in general payments, 2019–2025

Across 8 payments — averaging $28.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$125
  • Lilly USA, LLC$27
  • Ultragenyx Pharmaceutical Inc.$19
  • GSK$16
  • AstraZeneca$14
  • Sanofi$13
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$228 in reported general payments places this provider in the 50th percentile of 408 family medicine providers in South Dakota.

See all family medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$118,035
Medicare patients
473
Services billed
1,434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$86,823
OzempicSemaglutide62$75,703
MounjaroTirzepatide56$68,530
XareltoRivaroxaban32$40,652
CreonLipase/Protease/Amylase11$37,390
JardianceEmpagliflozin27$35,848
AbrysvoRsv Vacc, Pref A And Pref B/Pf96$30,934
MyrbetriqMirabegron33$20,714
ShingrixVaricella-Zoster Ge/As01b/Pf76$16,982
FarxigaDapagliflozin Propanediol13$16,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,110
Spiriva RespimatTiotropium Bromide16$10,605
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$8,879
Breo ElliptaFluticasone/Vilanterol11$8,222
Dexlansoprazole DrDexlansoprazole19$7,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$27$68,53056 claims
GSKShingrix, Trelegy Ellipta, Breo Ellipta$16$36,313104 claims
AstraZenecaFarxiga, Symbicort$14$24,21046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 408 family medicine providers in South Dakota.

Other family medicine in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →